INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC 13F/ADDVerified data

ARK Investment Management LLC bought NTLA

13F filer · Intellia Therapeutics, Inc. · Intellia Therapeutics Inc

Side
BUY
Δ value
$40.04M
Shares
2.37M
Price
$16.92
Executed
Not disclosed
Disclosed
Aug 14, 2026

NTLA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    ADD

  • Relative size+6 / 25

    $40.0M quarter-over-quarter change

  • Filing timing0 / 15

    Not applicable — 13F reports quarter-end holdings, execution dates are not disclosed

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

Other disclosed activity · NTLA

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
27
DP
Dube Michael PVP, Chief Accounting Officer
NTLAIntellia Therapeutics, Inc.
Open-market sale
SELL

Evidence

Verified data

Read directly from the primary public document; every field below is as reported by the filer.

Source

Document
SEC Form 13F-HR
Publisher
U.S. Securities and Exchange Commission (EDGAR)
Document ID
0001104659-26-096910

Timestamps

Event (reported)
Not reported
Published
Aug 14, 2026
Ingested by INSIDER
Nov 4, 22:39 UTC
Last re-read
Nov 5, 07:36 UTC

Extracted facts

Filer
ARK Investment Management LLC
Role
13F filer
Transaction
ADD
Asset
Intellia Therapeutics Inc
Ticker
NTLA
Shares
2.37M
Price per share
$16.92
Value
$40,040,114
Owned after transaction
16.88M shares

What this establishes

ARK Investment Management LLC reported this position change in a quarterly 13F holdings report. 13F shows quarter-end positions only — it does not say when during the quarter shares were bought or sold.

Extraction

Method
13F information table XML
Confidence
1.00
13F filer
ARK Investment Management LLCcik:0001697748
Issuer
Intellia Therapeutics, Inc.cik:0001652130

Revision history · 0

No field has changed since this record was first ingested.

Company events

No records

No material filings recorded for this issuer.

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    $44K
    2,641 sh
    Jul 1, 2026
    Jul 6, 2026
    traded Jul 1, 2026
    +5d
    SEC FORM 4

    Evidence

    9
    GJ
    Goodman JesseDirector
    NTLAIntellia Therapeutics, Inc.
    Grant or award
    A—
    13.3K sh
    Jun 9, 2026Jun 10, 2026
    traded Jun 9, 2026
    +1dSEC FORM 4

    Evidence

    17
    GJ
    Goodman JesseDirector
    NTLAIntellia Therapeutics, Inc.
    Grant or award
    A—
    9,200 sh
    Jun 9, 2026Jun 10, 2026
    traded Jun 9, 2026
    +1dSEC FORM 4

    Evidence